cdc-gov/monthly-nirsevimab-receipt-and-intent-reported-by-vdz4-qrri
Icon for Socrata external plugin
  •  
    Overview
  •  
    Tables
  •  
    REST API
  •  
    SQL Query
Open repository in Console
 
Readme
Updated 11 months ago
‧
Indexed 11 months ago

Monthly Nirsevimab Receipt and Intent Reported by Females Aged 18-49 Years Who Have a Baby <8 Months During the RSV Season, United States

Monthly Nirsevimab Monthly Nirsevimab Receipt and Intent Reported by Females Aged 18-49 Years With infants <8 Months During the RSV Season (born since April 1, 2024)

Monthly estimates of receipt and intent for nirsevimab reported by adult females aged 18–49 years with infants under the age of 8 months during the RSV season (born since April 1, 2024) using data from the National Immunization Survey–Adult COVID Module (NIS–ACM). (https://www.cdc.gov/nis/about/). The NIS–ACM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. All estimates are based upon parent-reported receipt of nirsevimab.

Querying over HTTP

Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:

curl https://data.splitgraph.com/sql/query/ddn \
    -H "Content-Type: application/json" \
    -d@-<<EOF
{"sql": "
    SELECT *
    FROM \"cdc-gov/monthly-nirsevimab-receipt-and-intent-reported-by-vdz4-qrri\".\"monthly_nirsevimab_receipt_and_intent_reported_by\"
    LIMIT 100 
"}
EOF

See the Splitgraph documentation for more information.

 
Preview
  • monthly_nirsevimab_receipt_and_intent_reported_by
     
    Left sidebar is currently unimplemented
     
     
     
     
    Right sidebar is currently unimplemented
Upstream Metadata
Common CoreHomepagehttps://www.cdc.gov/rsvvaxview/LanguageEnglishPublisherNational Center for Immunization and Respiratory Diseases (NCIRD)Bureau Code009:20Contact NameVaxView TeamProgram Code009:020Contact EmailVaxView@cdc.govUpdate FrequencyMonthlyGeographic CoverageUnited States- National, Region, State Temporal Applicability2024-2025
Data QualityFootnotesConfidence Intervals (CIs) describe the level of uncertainty around an estimate because a sample was taken. 95% CIs represent the range of values that would result if the data collection had been repeated many times. For a 95% confidence interval, if the sampling method is repeated many times, the true value would fall within this interval at least 95% of the time. Wider CIs reflect larger random error in estimates resulting from survey sampling. Estimates from the NIS–ACM may differ from estimates based on other data sources, and in addition to random error associated with taking a sample, are subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self-reported vaccination status. Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias. Estimates of nirsevimab receipt by infants born since April 1, 2024 include those who were born shortly before or are entering their first RSV season and do not account for the mother’s RSV vaccination status during pregnancy (Healthcare Providers: RSV Immunization for Children 19 Months and Younger | CDC) (https://www.cdc.gov/vaccines/vpd/rsv/hcp/child.html). National estimates include 50 states, Washington D.C., Guam, and Puerto Rico. Estimates are based on interviews conducted during Sunday through Saturday weeks assigned to the monthly analytic period, which may include some dates in the month before or after the specified analytic month. Unlike the weekly RSV vaccination coverage estimates, they are not cumulative estimates based on all interviews conducted to date. Suggested CitationNational Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention. Monthly Nirsevimab Receipt and Intent Among Females Aged 18-49 Years Who Have an Infant <8 Months During the RSV Season, United StatesGeospatial ResolutionNational, Regional, State

About

Monthly Nirsevimab Receipt and Intent Reported by Females Aged 18-49 Years Who Have a Baby <8 Months During the RSV Season, United States
11 months ago (updated)
11 months ago (indexed)
Loading...

Topics

  • iis
  • iqvia
  • nis-acm
  • nis-flu
  • rsv vaccination
  • + 1

Sources

License

Public Domain U.S. Government